What we do
Cancer cells exhibit altered transcriptional profiles when compared to their tissue of origin. Genetic alterations participate in promoting defective transcription, however they don't explain the full spectrum of aberrations found in malignant tissues. Gene expression is also controlled via modifications of the chromatin landscape including DNA methylation, histone modifications and chromatin remodelling. Our objective is to characterize the role of the chromatin landscape in oncogenesis and to understand how cancer cells reprogram the chromatin landscape to stop the treatment from working.
We have used breast cancer models to demonstrate that epigenetic reprogramming of the chromatin landscape promotes the expression of genes directly related to resistance to endocrine therapies. We can create epigenomic maps to study the regulatory networks of cancer cells and determine how these networks respond to therapies. Ultimately, we want to exploit epigenetic mapping to identify drug-responsive targets, biomarkers and develop novel compounds to interfere with reprogramming.
We are also interested in understanding the extent of interactions existing between genetic and epigenetic alterations. It is likely that cancer cells exploit both genetic and epigenetic mutations to promote proliferation, adaptation and invasion.
What’s going on
News from our lab
Luca Magnani and his group are actively involved in the organization of “Systems Epigenetics: Towards Precision Cancer Medicine” Conference which […]
FEBS Letters Cover Contest 2018 is the year of the 50th anniversary of FEBS Letters journal. For the occasion, the journal initiated a […]
This international meeting provided a forum for biologists, methods developers and computational modelers interested in understanding biology at single […]
New facts from the world
October is breast cancer awareness month, which is a worldwide annual campaign to increase awareness of the disease and to […]
In the next few years, it will be possible to identify cancers and determine prognosis from a simple blood analysis.
New research published in the journal, Clinical Cancer Research, shows the development of a technique allowing the identification of cancer mutations […]
A light-hearted but insightful satire of why you should be careful of getting your science from the press. Most of […]